Iterum Therapeutics Q2 EPS $(0.77) Beats $(0.80) Estimate
Portfolio Pulse from Benzinga Newsdesk
Iterum Therapeutics reported Q2 losses of $(0.77) per share, beating the analyst consensus estimate of $(0.80) by 3.75%. However, this represents a 63.83% increase in losses compared to the same period last year.

August 11, 2023 | 11:02 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Iterum Therapeutics' Q2 losses were less than expected, but significantly higher than last year. This mixed result could lead to uncertainty in the market.
While Iterum Therapeutics beat analyst estimates for Q2, the significant increase in losses compared to the same period last year could cause concern among investors. This could lead to uncertainty in the market, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100